Discounted Cash Flow
Novartis AG ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $48.5b | $6.7b | $10.4b | 13.8% | $2.82 |
| 2017 | $49.1b (1.2%) | $7.7b (14.8%) | $7.1b (-31.2%) | 15.7% (13.4%) | $3.28 (16.3%) |
| 2018 | $51.9b (5.7%) | $12.6b (63.7%) | $12.2b (71.6%) | 24.3% (54.9%) | $5.44 (65.9%) |
| 2019 | $47.5b (-8.5%) | $11.7b (-7.0%) | $8.1b (-33.9%) | 24.7% (1.7%) | $5.12 (-5.9%) |
| 2020 | $48.7b (2.4%) | $8.1b (-31.2%) | $10.8b (33.6%) | 16.6% (-32.8%) | $3.55 (-30.7%) |
| 2021 | $51.6b (6.1%) | $24.0b (197.6%) | $12.0b (11.2%) | 46.5% (180.5%) | $10.71 (201.7%) |
| 2022 | $50.5b (-2.1%) | $7.0b (-71.0%) | $10.8b (-10.1%) | 13.8% (-70.4%) | $3.19 (-70.2%) |
| 2023 | $45.4b (-10.1%) | $14.8b (113.5%) | $11.5b (6.2%) | 32.7% (137.5%) | $7.15 (124.1%) |
| 2024 | $50.3b (10.7%) | $11.9b (-19.6%) | $13.8b (20.4%) | 23.7% (-27.4%) | $5.92 (-17.2%) |
| 2025 | $54.5b (8.4%) | $14.0b (17.1%) | $15.2b (10.4%) | 25.6% (8.1%) | $7.21 (21.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.